$5.964
+0.016 (+0.26%)At close
ARTL News
ARTL Events
Artelo Biosciences Announces 1-for-9 Reverse Stock Split
Artelo Biosciences announced a 1-for-9 reverse stock split of the company's common stock. The company's common stock will begin trading on a split-adjusted basis on Nasdaq commencing at the market open on August 31. The reverse split is being effected in order to increase the price per share of the common stock to improve its marketability and liquidity.
Artelo Biosciences Receives Patent Approval for ART27.13 from Japan Patent Office
Artelo Biosciences announced that the Japanese Patent Office has issued a notification of allowance with a decision to grant for the company's patent application covering the intended commercial formulation of ART27.13, Artelo's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials. The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. These claims are consistent with those previously allowed in the United States and Europe, and all jurisdictions are expected to provide patent protection through 2041. This brings Artelo's intellectual property estate for ART27.13 to issued or allowance status in three major pharmaceutical markets, the United States, Japan, and Europe. ART27.13 is currently being evaluated in the Phase 2 portion of CAReS targeting cancer-related anorexia. Interim results from the CAReS Phase 2 demonstrated the ability of the drug to reverse cancer-related anorexia in all patients taking the highest dose of 1300 microgram whereas all the participants on placebo continued to lose weight throughout the study. ART27.13 is also being evaluated in the DREAM study, a pilot Phase 2 in people with glaucoma or ocular hypertension. Initial results are anticipated in Q4.
Artelo Biosciences Doses First Patient in DREAM Study
Artelo Biosciences announced the first patient has been dosed in the DREAM study, which will evaluate the effects of Artelo's orally administered synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.
Artelo Biosciences Unveils New Data for ART26.12 in Osteoarthritis Treatment
Artelo Biosciences announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 inhibitor, as a novel product candidate for the treatment of osteoarthritis pain. In the nonclinical OA study, oral administration of ART26.12 significantly reduced osteoarthritis-associated pain behaviors following both acute and chronic dosing over a four-week period, demonstrating efficacy comparable to naproxen, a widely prescribed nonsteroidal anti-inflammatory drug used to treat OA. ART26.12 produced distinct changes in endocannabinoids and other related bioactive lipids and proteins compared to naproxen, supporting a novel mechanism of action for ART26.12. Importantly, animals treated with ART26.12 exhibited significantly less stomach tissue damage, including non-glandular hyperkeratosis, compared to those receiving naproxen. Non-glandular hyperkeratosis is considered an early indicator of erosions and gastric ulcers, a well-recognized and potentially serious complication associated with chronic NSAID use. These findings suggest ART26.12 may offer effective pain relief with the potential for an improved gastrointestinal safety profile. Long-term treatment options for OA remain constrained by the safety concerns associated with chronic NSAID use, including gastrointestinal complications that contribute to significant morbidity and healthcare costs each year. These limitations highlight the need for differentiated therapies, and new preclinical findings further validate FABP5 as a promising target for the treatment of chronic pain while reinforcing the broad therapeutic potential of ART26.12. The data demonstrated that inhibition of FABP5 significantly alleviated osteoarthritis-associated pain, expanding the potential clinical utility of ART26.12 beyond neuropathic pain into one of the largest and most prevalent chronic pain markets. Importantly, ART26.12 delivered pain relief comparable to naproxen while exhibiting significantly less gastric tissue damage in preclinical studies, supporting the potential for an improved gastrointestinal safety profile. Collectively, these findings further support the continued development of ART26.12 as a differentiated, non-opioid pain therapy with the potential to address multiple chronic pain indications through its novel mechanism of action. Preparations are underway for conducting a clinical multiple ascending repeat dose study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. Artelo anticipates enrollment will commence during the fourth quarter of this year.
Artelo Biosciences Announces ART27.13 Results in Neuropathic Pain Studies
Artelo Biosciences announced results from nonclinical studies in neuropathic pain with ART27.13, the company's proprietary peripherally restricted cannabinoid receptor agonist, currently in Phase 2 clinical development evaluating patients experiencing cancer-related anorexia cachexia syndrome. To determine whether ART27.13 has the potential to address neuropathic pain in cancer patients, researchers at Artelo investigated its proprietary dual cannabinoid agonist in a nonclinical model of paclitaxel-induced peripheral neuropathy, a debilitating side effect that affects approximately 60%-80% of patients receiving paclitaxel. Results demonstrated that repeated dosing with ART27.13 reduced neuropathic pain-associated behaviors in both male and female paclitaxel-treated animals, supporting further exploration of the compound in oncology supportive care settings.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.